DENVER, Colo. (247marketnews.com) -- This week’s action puts Alector (NASDAQ:ALEC), NeOnc Technologies (NASDAQ:NTHI), WISeQey (NASDAQ:WKEY), Veea (NASDAQ:VEEA), and Stablecoin Development Corporation (NYSEAMERICAN:SDEV) squarely in that conversation.
Alector Lands A $1.27 Billion Genentech Deal
Alector (NASDAQ:ALEC) has transformed its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX:RHHBY). The deal calls for $100 million upfront, up to $1.17 billion in development, regulatory and commercial milestones, plus tiered royalties on net sales. Genentech takes responsibility for development, regulatory activities, manufacturing and commercialization worldwide. The agreement immediately gave ALEC a major market catalyst, with Reuters reporting a sharp premarket jump following the announcement.
The bigger story is the technology behind AL050. The investigational therapy combines an engineered glucocerebrosidase enzyme with Alector’s proprietary Alector Brain Carrier (ABC) platform, designed to transport therapeutic payloads across the blood-brain barrier. The program targets GCase deficiency, a biological mechanism increasingly associated with Parkinson’s disease, particularly among patients carrying GBA1 mutations.
“The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain,” said Alector CEO Arnon Rosenthal. “AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier.” Importantly for investors, Alector retains ownership of ABC and rights to apply the platform across its wholly owned pipeline.
The deal also strengthens Alector’s financial runway. The company said its preliminary September 30 cash, cash equivalents and marketable securities totaled approximately $138.7 million, increasing to approximately $223.7 million pro forma after the initial Genentech-related payments and other transaction effects. Management said the resources are expected to fund operations into 2029, while the company continues advancing its brain-enabled Alzheimer’s, tau and alpha-synuclein programs.
NeOnc Heads Toward Critical FDA Checkpoint
NeOnc Technologies (NASDAQ:NTHI) is moving toward a major regulatory catalyst, with the FDA scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212. NeOnc plans to seek feedback on the proposed patient population, Phase 2 design, endpoints, dose selection and evidence that could eventually support a marketing application. The meeting itself does not establish FDA agreement on a trial design or an accelerated-approval pathway, but it represents a potentially important inflection point for the program.
NEO212 enters that meeting with Phase 1 dose escalation completed and a recommended Phase 2 dose of 610 mg, following a protocol-defined maximum tolerated dose of 810 mg. The company has reported preliminary observations in heavily pretreated patients, including a recurrent glioblastoma patient who experienced approximately 60% tumor reduction followed by disease control extending beyond 21 months. The early data remain limited by the small Phase 1 population, making the next stage of clinical development particularly important.
Meanwhile, NeOnc’s NEO100 program has already delivered a significant clinical catalyst. In its Phase 2a study in recurrent or progressive IDH1-mutant high-grade glioma, the company reported six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047 and median overall survival of 26.09 months. The study was small and open-label, so additional clinical and regulatory validation remains necessary, but the results have materially raised the visibility of the NEO platform.
One of NTHI’s most interesting differentiators is its intranasal, nose-to-brain delivery strategy, designed to address the blood-brain barrier challenge by delivering therapeutics through the nasal passage and into the central nervous system. For investors, that creates a platform story rather than a single-drug story: NEO100 and NEO212 are separate clinical shots on goal, while the underlying delivery technology could potentially support additional CNS applications. Management has also disclosed substantial open-market purchases by executives following the NEO100 data.
WISeQey’s Space Spinout Hits Nasdaq
WISeQey (NASDAQ:WKEY) is entering a new phase as its satellite subsidiary, WISeSat.Space (NASDAQ:SAIQ), becomes a separately traded Nasdaq company. The business combination with Columbus Acquisition Corp. closed October 1, 2026, with SAIQ beginning Nasdaq trading on October 2. WISeSat.Space is positioning itself around post-quantum-secure satellite communications, IoT connectivity and trusted digital identity.
The strategy effectively extends WISeQey’s cybersecurity ecosystem from chips, devices and digital identity into space. WISeSat.Space says it has deployed satellites since 2024 and is targeting applications including remote monitoring, logistics, defense and infrastructure management. CEO Carlos Moreira described the Nasdaq listing as “an extraordinary milestone” and said the company’s ambition is to combine satellite communications with “digital identity, secure chips and post-quantum technologies.”
The parent-company backdrop adds another layer. WISeQey reported approximately 116% year-over-year first-half 2026 revenue growth to $11.4 million, approximately $495 million in cash and restricted cash at June 30, and reaffirmed 2026 revenue-growth guidance of 50% to 100%. The company has also highlighted its Quantum Spatial Orbital Cloud strategy and continued development of post-quantum security and satellite infrastructure.
There is also a direct financial connection between SAIQ and WISeQey ecosystem company SEALSQ (NASDAQ: LAES). At the transaction closing, SEALSQ received 1,040,478 WISeSat.Space ordinary shares and an equal number of Class F shares in exchange for its SpaceAIQ stake. Separately, SEALSQ invested through a PIPE at $10.79 per share, receiving 926,784 SAIQ ordinary shares. The agreement includes price protection that may result in additional shares if SAIQ trades below the purchase price at the applicable 60-day measurement point.
Veea’s VEEA Run Gets Commercial AI Catalyst
Veea (NASDAQ:VEEA) has emerged as another high-volatility name attracting attention as its edge-AI and intelligent-connectivity story picks up commercial traction. On October 1, the company announced an agreement with TROLLEE Holdings for the phased deployment of VeeaONE solutions across 1,000 unattended stores, beginning with up to 50 locations. Veea said typical configurations are expected to include VeeaHubs integrated with AI compute and related accessories at an estimated $1,000-$2,000 per store.
The agreement is notable because it moves the Veea story beyond technology demonstrations and toward a potentially repeatable commercial deployment model. Planned applications include loss prevention, store and shopper safety, predictive maintenance, store monitoring and other smart-retail functions. The company’s VeeaONE platform combines local AI processing, secure connectivity and remote management.
The TROLLEE relationship is not new. Veea and TROLLEE have been collaborating for years, and in June the companies announced an expanded strategic partnership combining Veea’s AI-powered, cybersecure edge-cloud computing and AdEdge contextual advertising engine with TROLLEE’s smart carts and retail robotics technology.
The company has also been expanding its channel strategy. In August, Veea announced a technology-services distribution agreement with Telarus, giving Telarus’ partner network access to Veea’s secure connectivity, edge computing and AI-enabled solutions.
SDEV At Center of Crypto-Treasury Trade
Stablecoin Development Corporation (NYSEAMERICAN:SDEV) represents a very different type of market story. Formerly NovaBay Pharmaceuticals, the company changed its name in April 2026 as it pivoted toward an on-chain holding-company model, with the Sky Protocol ecosystem and its SKY token as the centerpiece of its digital-asset strategy. The company’s common stock began trading under the SDEV ticker on NYSE American in April.
The scale of the digital-asset position is what makes SDEV unusual. As of September 13, the company reported holding approximately 2.315 billion SKY tokens, representing roughly 10% of the total SKY supply. SDEV describes SKY as its principal treasury asset and says its strategy is designed to provide long-duration participation in protocol-aligned digital-asset ecosystems while maintaining public-company governance and risk-management disciplines.
The company is not simply holding the asset passively. SDEV has deployed its SKY holdings in staking activities within the Sky Protocol ecosystem and reported $2.2 million of staking revenue during the second quarter and $4.7 million during the first half of 2026. At the same time, the company reported a $50.6 million non-cash unrealized loss on digital assets and a $53.8 million operating loss for the second quarter, illustrating both the potential income stream and the substantial volatility inherent in the strategy.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.